Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...

Eli Lilly wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Senator Ron Wyden (D-Oregon) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 21st, the Senator disclosed that they had bought between $50,001 and $100,000 ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen ...

Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations to expand radiopharmaceuticals and metabolic-associated ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...